CVOT, notable for comparing the two drugs, tirzepatide showed significantly greater improvements in major kidney outcomes vs dulaglutide.

Multiple Late-Stage Data Readouts Reinforce Telitacicept’s Broad Potential Across Autoimmune DiseasesExpansion of Executive Leadership and Board ...

Good morning, everyone. My name is Dina Elmonshed, one of the U.S. biotech analysts here at UBS. And joining me today is the President and CEO of Vertex Pharmaceuticals, Reshma Kewalramani. Thank you ...

Multiple Late-Stage Data Readouts Reinforce Telitacicept's Broad Potential Across Autoimmune DiseasesExpansion of Executive Leadership and Board Strengthens Global Development Capabilities Expected gr ...

Q3 2025 revenue of €143.1 million for YORVIPATH® and €50.7 million for SKYTROFA® - Q3 2025 operating profit of €11.0 million - TransCon® CNP (navepegritide) under FDA Priority Review for the ...

Nearly two years ago, Chad Gluss went into cardiac arrest and wound up needing a heart transplant. In January, he will be ...

Beets are a root vegetable that may have benefits for blood pressure management, athletic performance, and more.

Humacyte, Inc. ( HUMA) Q3 2025 Earnings Call November 12, 2025 8:00 AM EST Good morning, ladies and gentlemen, and welcome to the Humacyte's Third Quarter Results Conference Call. [Operator ...

High quality luxurious interior. Huge amounts of space in the back. Long wheelbase versions available. Efficient Dynamics means good economy and low CO2.

Ligand is increasing its 2025 full year financial guidance. The Company now expects total core revenue of $225 million to $235 million (previously $200 million to $225 million) and core adjusted ...

Detailed price information for Gilead Sciences Inc (GILD-Q) from The Globe and Mail including charting and trades.